Concepedia

Author

Li Zhang

Sun Yat-sen UniversityORCID

Also Known As

Jianying Zhou, L Zhang, L. Zhang, Li ZHANG, Li Zhang, Michelle Xia, S. Sheng, Simon Keely, Tingting Xu, Xin Yi

448

Publications

13.8K

Citations

52

H-Index

98

Concepts

All Affiliations

Sun Yat-sen UniversitySun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaChinese Academy of Medical Sciences & Peking Union Medical CollegeShanghai Chest Hospital
LZ

About

Li Zhang is an author at Sun Yat-sen University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

32

62

5.7K

2

Health Sciences

15

17

1.3K

3

Engineering

2

2

81

4

Public Health

1

1

61

5

Anatomy

1

1

20

Li Zhang

×

147

Publications

11.4K

Citations

45

H-Index

YearCitations

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne,

The Lancet Oncology

2016

1.1K

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen, Wenfeng Fang, Jianhua Zhan,

Journal of Thoracic Oncology

2015

672

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang,

JAMA Oncology

2018

591

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang, Yan Huang, Shaodong Hong,

The Lancet

2016

515

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang, Yunpeng Yang, Yuxiang Ma,

The Lancet Oncology

2018

495

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

D. Ross Camidge, Rafał Dziadziuszko, Solange Peters,

Journal of Thoracic Oncology

2019

488

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li,

The Lancet Oncology

2021

429

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Yi‐Long Wu, Jin Soo Lee, Sumitra Thongprasert,

The Lancet Oncology

2013

304

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana,

The Lancet Respiratory Medicine

2019

268

Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial

Liangjing Lu, Chengxiang Dai, Zhongwen Zhang,

Stem Cell Research & Therapy

2019

248

Page 1